Artelo Biosciences (ARTL) EBITDA (2014 - 2025)

Artelo Biosciences (ARTL) has reported EBITDA for 12 consecutive years, with -$2.8 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, EBITDA rose 26.92% year-over-year to -$2.8 million in Q4 2025; TTM through Dec 2025 was -$11.4 million, a 12.82% decrease from a year earlier, with the FY2025 full-year figure at -$11.4 million, down 12.82% from the prior year.
• EBITDA was -$2.8 million for Q4 2025 at Artelo Biosciences, up from -$3.1 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.2 million in Q3 2024 and troughed at -$3.8 million in Q4 2024.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 54.28% in 2024 and sank 158.49% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$2.6 million in 2021, then tumbled by 36.21% to -$3.5 million in 2022, then grew by 6.79% to -$3.2 million in 2023, then retreated by 17.65% to -$3.8 million in 2024, then grew by 26.92% to -$2.8 million in 2025.
• The last three EBITDA figures came in at -$2.8 million (Q4 2025), -$3.1 million (Q3 2025), and -$3.2 million (Q2 2025), per Business Quant data.